Carving out a clinical role as one of the key tools in personalized medicine, optical molecular imaging systems are expected to generate $400 million in global sales by 2014 and nearly $1 billion by the end of the decade, according to a report by market research firm Strategies Unlimited.
However, these gains will hinge on partnerships with key medical equipment vendors, outcomes of clinical trials assessing imaging agents, regulatory approvals, patent litigation, and decisions about insurance reimbursement, the Mountain View, CA-based company said.
The research market will continue at a steady pace as optical molecular imaging becomes more widely used for drug discovery and preclinical studies, Strategies Unlimited said. On the clinical side, recent imaging agent advances will power the transition of these technologies to clinical settings, according to the firm.
Copyright © 2010 AuntMinnie.com
